Trends and Outcomes of Hospitalized Influenza Patients With End-Stage Kidney Disease: Insights From the National Inpatient Sample 2010–2019

Guangchen Zou 1, Hongli Liu 2, Kaiqing Lin 1, Kaiwen Zhu 2, Tien-Chan Hsieh 1

1. Internal Medicine, Danbury Hospital, Danbury, USA 2. Internal Medicine, Rochester Regional Health, Rochester, USA

Corresponding author: Guangchen Zou, kenzou@outlook.com

Abstract

Introduction

Influenza causes significant morbidity and mortality annually in the United States (US) and people with chronic medical conditions are thought to be at higher risk for severe disease and death. Infection is a leading cause of death for patients with end-stage kidney disease (ESKD). We used a national-level inpatient database to study the trend of influenza hospitalizations and in-hospital mortality for patients without and with ESKD.

Methods

The National Inpatient Sample (NIS) 2010-2019 was used. A primary diagnosis of influenza was identified using ICD-9-CM (487.X, 488.X) and ICD-10-CM codes (J09.X, J10.X, J11.X). ESKD was identified using a validated algorithm identifying patients with a diagnosis of ESKD or procedure code for dialysis and excluding patients with a diagnosis of acute kidney injury. Other diagnoses and procedures were identified using validated algorithms based on ICD-9-CM, ICD-10-CM, and ICD-10-PCS codes. Discharge-level weights were used to estimate the total number of admissions in the NIS universe. Weighted multivariable logistic regression was performed to study the association between ESKD and in-hospital death.

Results

131,942 admissions with a primary diagnosis of influenza with 4,647 admissions for ESKD patients among them were included in our analysis. Admissions varied by influenza season and ESKD patients accounted for 2.91% to 3.65% of all influenza admissions each season. 2,081 influenza patients (1.58%) died in the hospital and 115 patients with influenza and ESKD (2.47%) died in the hospital. Age-adjusted in-hospital mortality varied from season to season but was consistently higher in ESKD patients (2.25% vs 1.38%). ESKD was a risk factor for in-hospital death (OR 1.26, 95% CI 1.15-1.38) after adjusting for age, gender, primary payer, heart failure, chronic lung disease, obesity, drug abuse, immunocompromised status, bacterial pneumonia, the Charlson Comorbidity Index, and the influenza season.

Conclusion

ESKD patients accounted for a significant proportion of influenza hospitalizations in the US from 2010-11 to the 2018-19 influenza season. Among people hospitalized primarily for influenza, age-adjusted in-hospital mortality varied from season to season and was consistently higher in ESKD patients. For people hospitalized primarily for influenza, ESKD was an independent risk factor for in-hospital death.
Materials And Methods

The NIS from the years 2010 to 2019 was used. Patients with a primary diagnosis of influenza were identified using the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes (487.X, 488.X) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes (I09.X, J10.X, J11.X). Cases up to July were counted in the previous influenza season while cases starting in August were counted in the next influenza season. ESKD was identified using a previously validated algorithm which identified patients that (1) carried a diagnosis code for ESKD or (2) carried a procedure code for hemodialysis or peritoneal dialysis but (3) did not carry a diagnosis code of acute kidney injury [4]. Immunocompromised patients were identified using a previously validated algorithm identifying patients with organ transplants, HIV, malignancies, certain rheumatologic disorders, and other immunodeficiencies using ICD-9-CM and ICD-10-CM codes [5]. Individual diagnosis categories of the Charlson Comorbidity Index were identified, and the index was calculated using an algorithm developed by Deyo and colleagues and modified by Quan and colleagues using codes from the Manitoba Centre for Health Policy [6–8]. Bacterial pneumonia was identified using ICD-9-CM codes (481.X, 482.X) and ICD-10-CM codes (J13.X, J14.X, J15.X) [9]. Invasive mechanical ventilation was identified using a validated algorithm using ICD-9-CM codes and ICD-10-CM Procedure Coding System (ICD-10-PCS) codes [10]. Discharge-level weights provided in the NIS were used to estimate the total number of admissions for patients hospitalized with a primary diagnosis of influenza and the ESKD patients among them in the NIS universe, and the numbers were compared to the estimated number of all influenza-related hospitalizations for each influenza season from the CDC. In-hospital mortality rates were adjusted for age based on the age distribution of all admissions included in the analysis. Linear regression was performed to test the correlation between the estimated total number of influenza primary diagnosis admissions in the NIS universe and the CDC’s estimated number of influenza-related admissions for each influenza season. Weighted multivariable logistic regression was performed to study the associations between ESKD and in-hospital mortality, using age, gender, primary payer, heart failure, chronic lung disease, obesity, drug abuse, and immunocompromised status, bacterial pneumonia, the Charlson Comorbidity Index, and the influenza season as covariates. Data processing was done using SAS® version 9.4 (SAS® Institute, Inc., Cary, NC). Some of the diagnosis and procedure codes used were listed in Table 3 in Appendices. Diagnosis and procedure codes used to identify the immunocompromised status and the Charlson Comorbidity Index can be found in the relevant references. Statistical analyses were performed using R version 4.0.3 (R Foundation). The study only used de-identified data from a public database and was exempt from IRB approval at both of our institutions.

Results

137,300 admissions for patients aged 18 or above were identified as having a primary diagnosis of influenza; 5,305 admissions before August 2010 or after July 2019 were removed and 53 were removed due to missing mortality data. 131,942 admissions were included in our analysis among which 4,647 were identified as admission for patients with ESKD (Figure 1).
Baseline characteristics of the admissions were listed in Table 1.

| Baseline Characteristics | Non ESKD (n=127058) | ESKD (n=4647) | p value |
|--------------------------|---------------------|---------------|---------|
| Age group (%)            |                     |               |         |
| 18-49                    | 1731 (10.0)         | 82 (13.4)     | <0.001  |
| 50-65                    | 3092 (17.8)         | 174 (30.6)    | <0.001  |
| >65                      | 12540 (72.2)        | 358 (58.3)    |         |
| Sex (%)                  |                     |               |         |
| Male                     | 55377 (43.5)        | 2322 (50.0)   | <0.001  |
| Female                   | 71910 (56.5)        | 2325 (50.0)   |         |
| Race (%)                 |                     |               |         |
| Caucasian                | 88837 (73.0)        | 1692 (42.1)   | <0.001  |
| African American         | 15257 (12.6)        | 1436 (32.2)   |         |
| Hispanic                 | 10027 (8.9)         | 659 (15.4)    |         |
| Asian or Pacific Islander| 2862 (2.4)          | 211 (4.7)     |         |
| Native American          | 671 (0.5)           | 106 (2.4)     |         |
| Other                    | 3170 (2.6)          | 143 (2.2)     |         |
| Primary payer (%)        |                     |               |         |
| Medicare                 | 85213 (67.0)        | 3618 (82.3)   | <0.001  |
| Medicaid                 | 11983 (9.3)         | 362 (7.8)     |         |
| Private insurance        | 22872 (18.0)        | 369 (8.0)     |         |
| Self-pay                 | 4523 (3.6)          | 34 (0.7)      |         |
| Other/no charge          | 2641 (2.1)          | 55 (1.2)      |         |
| All chronic lung diseases (%) | 54435 (42.8) | 1635 (38.2) | <0.001  |
| COPD (%)                 | 33046 (27.5)        | 1052 (23.4)   | <0.001  |
| Immuno-compromised status (%) | 22521 (18.1) | 1436 (32.2) | <0.001  |
| Drug use (%)             | 3408 (2.7)          | 111 (2.4)     | 0.222   |
| Heart failure (%)        | 26026 (20.8)        | 2036 (43.8)   | <0.001  |
| Diabetes without complications (%) | 31607 (24.1) | 1228 (28.4) | 0.037   |
| Diabetes with complications (%) | 10487 (8.2) | 2055 (44.2) | <0.001  |
| HIV/AIDS (%)             | 599 (0.5)           | 54 (1.2)      | <0.001  |
| Charlson Comorbidity Index (mean (SD)) | 1.62 (1.31) | 3.01 (1.36) | <0.001  |
| Bacterial pneumonia (%)  | 8762 (6.8)          | 321 (6.0)     | 0.873   |
| Invasive mechanical ventilation (%) | 3219 (2.5) | 138 (3.0) | 0.086   |

**TABLE 1: Baseline characteristics of admissions included in the study. The admissions all carried a primary diagnosis of influenza and 4647 admissions were for patients with ESKD.**

IQR: interquartile range. SD: standard deviation.

Using discharge-level weight provided in the NIS, the estimated number of hospital admissions with a primary diagnosis of influenza in the NIS universe varied from year to year and was the highest in the 2017-2018 influenza season. This followed the same trend as the total number of influenza-related hospitalizations in the US estimated by the CDC (linear regression $R^2 = 0.69$, $p = 0.005$). For each influenza season analyzed, ESKD patients accounted for 2.91% to 3.65% of all admissions with a primary diagnosis of influenza. (Table 2; Figure 2A).
FIGURE 2: (A) Trends of estimated hospitalizations with a primary diagnosis of influenza and for ESKD patients with a primary diagnosis of influenza (magnified 10 times) in the NIS universe, compared with influenza-related hospitalizations in all of the US as estimated by the CDC for each influenza season from 2010 to 2019. Hospitalizations in the NIS universe were estimated using discharge-level weights provided in the NIS. (B) Age-adjusted in-hospital mortality for all admissions with a primary diagnosis of influenza and patients with ESKD and a primary diagnosis of influenza in the NIS for each influenza season from 2010 to 2019.
Among the 131,492 admissions analyzed, 2,081 patients died in the hospital (1.58%). Among the 4,647 admissions where ESKD patients were hospitalized with a primary diagnosis of influenza, 115 died (2.47%). Age-adjusted in-hospital mortality was 1.38% for all influenza patients and 2.25% for patients with ESKD. The age-adjusted in-hospital mortality rate varied from influenza season to influenza season but was consistently higher in ESKD patients (Figure 2B). Among the influenza seasons analyzed, the age-adjusted in-hospital mortality rate was highest for ESKD patients in the 2010-11 (3.42% vs 2.02% for all patients) and the 2014-15 influenza season (3.58% vs 1.73% for all influenza patients). These two seasons were also among the seasons with the highest in-hospital mortality for all influenza patients (Table 2). The age-adjusted in-hospital mortality rate was the lowest in influenza season 2016-17 both for ESKD patients with influenza (1.08%) and all influenza patients (0.95%). In multivariable logistic regression, ESKD was associated with higher in-hospital mortality (OR 1.26, 95% CI 1.15-1.38) for patients hospitalized with a primary diagnosis of influenza after adjusting for age, gender, primary payer, heart failure, chronic lung disease, obesity, drug use, immunocompromised status, bacterial pneumonia, the Charlson Comorbidity Index, and the influenza season (Figure 3, Table 4 in Appendices). Other risk factors for in-hospital death include older age (OR 1.32, 95% CI 1.29-1.34 for every 10 years), heart failure (OR 1.67, 95% CI 1.58-1.75), immunocompromised status (OR 1.26, 95% CI 1.20-1.32), bacterial pneumonia (OR 2.59, 95% CI 2.45-2.74), and a higher Charlson comorbidity index (OR 1.29, 95% CI 1.26-1.31).

### Table 2: Estimated number of admissions with a primary diagnosis of influenza and estimated number of admissions for ESKD patients with a primary diagnosis of influenza in the NIS universe using discharge-level weights along with age-adjusted in-hospital mortality rate for both groups calculated using non-weighted data. CDC estimated influenza-related hospitalizations in all of the US were also included for comparison.

*Data from the CDC.
FIGURE 3: Forest plot of odds ratios from multivariable logistic regression analysis of in-hospital death using ESKD, age, gender, primary payer, heart failure, chronic lung disease, obesity, drug use, immunocompromised status, bacterial pneumonia, the Charlson Comorbidity Index, and the influenza season as variables and weighted for discharge weight. For patients hospitalized with a primary diagnosis of influenza, ESKD was associated with an odds ratio of 1.26 (95% CI 1.15-1.38) for in-hospital death adjusting for other factors.

ESKD: end-stage kidney disease. CHF: congestive heart failure. CI: confidence interval.

Discussion
The study has important limitations. The NIS does not include admissions from the Veteran Affairs hospitals, Indian Health Service hospitals, and other federal hospitals. Certain data sources did not release discharge records for HIV/AIDS patients to the AHRQ [11], so the HIV/AIDS population may have been underrepresented in the data. The diagnoses or procedures identified using diagnosis and procedure codes may have been affected by coding practices [12]. Important information such as medication use, and influenza vaccination status were not available. Other confounders may also have existed that were not adjusted for when analyzing in-hospital mortality. Furthermore, the different factors used in the analysis may not have been completely independent. Despite these, this large and relatively representative sample population gave us unique insights into the disease burden of influenza in ESKD patients and the higher risk of death ESKD patients faced when they were admitted for influenza.

Inpatient databases can be a valuable resource in studying influenza burden and outcomes. Although inpatient death from confirmed influenza cases grossly underestimated all influenza-related deaths, it has been shown to correlate very well with mortality burden estimated using the excess mortality method [13]. Similarly, in our study, although the number of estimated admissions with a primary diagnosis of influenza in the NIS universe is much lower than the number of CDC estimated national influenza-related admissions for each influenza season, the correlation was robust.

Of note, though the age-adjusted inpatient mortality rate was the lowest in the 2016-17 influenza season, admission numbers were actually relatively high (Figure 2). A similar pattern was found in the Society of Actuaries analysis of the 2016-17 influenza season using data from the CDC [14]. The reason for this was unclear. The variations in admission numbers and age-adjusted inpatient mortality from season to season were probably due to many factors including the characteristics of the predominant influenza strains of the season and the immunity level in the population.

The association between ESKD and higher in-hospital mortality is not surprising. Chronic kidney disease is associated with higher mortality for patients with respiratory tract infections [15] and infections of various kinds are a leading cause of death for patients with ESKD, accounting for up to 56% of all-cause mortality by some estimates [16,17]. In the US, seasonal variations in all-cause mortality of ESKD patients correlated with community influenza-like illness activity, suggesting more than 1,000 deaths in ESKD patients per year were potentially attributable to influenza-like illness [18].

Interestingly, in our model, certain comorbidities such as chronic lung disease were associated with a decreased risk of in-hospital death. A similar pattern has been found in other studies looking at risk factors
for inpatient mortality of influenza or pneumonia using national inpatient registries [19,20]. One hypothesis is that this might be due to a lower threshold for admission in such patients resulting in patients with less severe influenza or pneumonia being admitted. People with high-risk medical conditions such as chronic lung disease were also more likely to be vaccinated [21], this could have potentially lowered their risk.

Vaccination may potentially decrease the disease burden of influenza for ESKD patients. Though high-quality evidence is scarce on the effectiveness of influenza vaccination in the ESKD population, a pooled analysis of observational data suggested vaccination may protect against hospitalization and death in ESKD patients [22]. Influenza vaccination rates have improved over the years for ESKD patients in the US, but significant disparities exist among different dialysis facilities [23]. Providers should continue to make efforts to encourage ESKD patients to get influenza vaccines each season.

Conclusions
ESKD patients accounted for 2.91% to 3.65% of hospitalizations with a primary diagnosis of influenza in the US from 2010-11 to the 2018-19 influenza season. The estimated number of admissions with a primary diagnosis of influenza in the NIS universe correlated with the CDC estimates of influenza-related hospitalizations during this period. Age-adjusted in-hospital mortality varied from influenza season to influenza season. Age-adjusted in-hospital mortality for EKSD patients hospitalized with a primary diagnosis of influenza during this time was consistently higher than that for all patients hospitalized primarily for influenza. For people hospitalized primarily for influenza, ESKD was an independent risk factor for in-hospital death (OR 1.26, 95% CI 1.15–1.38).

Appendices

| Diagnosis/Procedure                  | ICD-10 CM/ICD-10 PCS codes | ICD-9 codes |
|-------------------------------------|-----------------------------|-------------|
| End-stage kidney disease            | Z092, N186, Z0915, Z4931, Z4961, Z4962, Z4981, Z4982 | 5856, 3995, 5498, V4511, V4512, V590, V591, V592, V593, V594, V595, V596, V597 |
| Hemodialysis                        | 5AC1*                       | 3066        |
| Peritoneal dialysis                 | 5E1M39Z                     | 5498        |
| Acute kidney injury                 | N17*                        | 554*        |
| Bacterial pneumonia                 | J13*, J14*, J15*            | 481*, 482*  |
| Invasive mechanical ventilation     | 5A10G5Z, 5A19G5Z, 5A19G5Z, 5A19G5Z, 5B172Z, 5B183Z | 96.04, 96.05, 96.07, 96.08, 96.09 |

TABLE 3: Diagnosis and procedure codes used to identify some specific diagnoses and procedures.

| Characteristic          | OR 1         | 95% CI 1     | p-value |
|-------------------------|--------------|--------------|---------|
| ESKD                    | 1.26         | 1.15, 1.38   | <0.001  |
| Age (10 years)          | 1.22         | 1.29, 1.34   | <0.001  |
| Female gender           | 0.92         | 0.88, 0.95   | <0.001  |
| Race                    |              |              |         |
| White                   | —            | —            |         |
| Black                   | 0.71         | 0.66, 0.76   | <0.001  |
| Hispanic                | 0.69         | 0.62, 0.76   | 0.002   |
| Asian or Pacific islander| 0.83       | 0.73, 0.95   | 0.007   |
| Native American         | 1.01         | 0.72, 1.29   | >0.0      |
| Other                   | 1.06         | 0.98, 1.23   | 0.3      |
| Primary payer           |              |              |         |
### Table 4: Results of multivariable logistic regression performed to study the association between ESKD and in-hospital death, using age, gender, primary payer, heart failure, chronic lung disease, obesity, drug use, immunocompromised status, bacterial pneumonia, the Charlson Comorbidity Index, and the influenza season as covariates and weighted for discharge-level weight.

|                         | OR     | 95% CI     | p-value |
|-------------------------|--------|------------|---------|
| Medicare                | —      | —          | —       |
| Medicaid                | 1.29   | 1.17, 1.42 | <0.001  |
| Private insurance       | 1.32   | 1.24, 1.41 | <0.001  |
| Self-pay                | 1.63   | 1.41, 1.87 | <0.001  |
| No charge               | 1.06   | 0.81, 1.37 | 0.8     |
| Other                   | 2.16   | 1.89, 2.46 | <0.001  |
| Heart failure           | 1.67   | 1.58, 1.77 | <0.001  |
| Chronic lung disease    | 0.78   | 0.74, 0.81 | <0.001  |
| Immunocompromised status| 1.26   | 1.20, 1.33 | <0.001  |
| Obesity                 | 0.83   | 0.77, 0.89 | <0.001  |
| Drug use                | 0.86   | 0.72, 1.01 | 0.686   |
| Bacterial pneumonia     | 2.59   | 2.45, 2.74 | <0.001  |
| Charlson Comorbidity Index | 1.29  | 1.26, 1.33 | <0.001  |
| Influenza season         |        |            |         |
| 2010-11                 | —      | —          | —       |
| 2011-12                 | 0.55   | 0.46, 0.66 | <0.001  |
| 2012-13                 | 0.63   | 0.57, 0.70 | <0.001  |
| 2013-14                 | 0.94   | 0.85, 1.04 | 0.2     |
| 2014-15                 | 0.69   | 0.63, 0.76 | <0.001  |
| 2015-16                 | 0.72   | 0.64, 0.80 | <0.001  |
| 2016-17                 | 0.38   | 0.34, 0.42 | <0.001  |
| 2017-18                 | 0.45   | 0.41, 0.49 | <0.001  |
| 2018-19                 | 0.44   | 0.39, 0.50 | <0.001  |

1 OR = Odds Ratio, CI = Confidence Interval

---

**Additional Information**

**Disclosures**

**Human subjects:** All authors have confirmed that this study did not involve human participants or tissue. **Animal subjects:** All authors have confirmed that this study did not involve animal subjects or tissue. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

**References**

1. Past Seasons Estimated Influenza Disease Burden. (2022). Accessed: April 12, 2022: https://www.cdc.gov/flu/about/burden/past-seasons.html.
2. Martínez A, Soldevila N, Romero-Tamarit A, et al.: Risk factors associated with severe outcomes in adult hospitalized patients according to influenza type and subtype. PLoS One. 2019, 14:e0210355.
HCUP-US NIS Overview. (2022). Accessed: April 19, 2022: https://www.hcup-us.ahrq.gov/nisoverview.jsp.

Gibertoni D, Voci C, Iommi M, D'Ercole B, Mandreoli M, Santoro A, Mancini E: Developing and validating an algorithm to identify incident chronic dialysis patients using administrative data. BMC Med Inform Decis Mak. 2020, 20(185). 10.1186/s12911-020-01296-x.

Greenberg JA, Hohmann SF, Hall JB, Kress JP, David MZ: Validation of a method to identify immunocompromised patients with severe sepsis in administrative databases. Ann Am Thorac Soc. 2016, 13:255-8. 10.1513/AnnalsATS.201507-415BC.

Deyo RA, Cherkin DC, Ciol MA: Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992, 45:613-9. 10.1016/0895-4356(92)90133-8.

Quan H, Sundararajan V, Halfon P, et al.: Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005, 43:1130-9. 10.1097/01.mlr.0000182534.19832.83.

Concept: Charlson Comorbidity Index | MCHP Concept Dictionary and Glossary for Population-Based Research | Max Rady College of Medicine | University of Manitoba. (2022). Accessed: April 19, 2022: http://appserv.cpe.umanitoba.ca/viewConcept.php.

Skull SA, Andrews RM, Byrne GB, Campbell DA, Nolan TM, Brown GV, Kelly HA: ICD-10 codes are a valid tool for identification of pneumonia in hospitalized patients aged ≥ or = 65 years. Epidemicol Infect. 2008, 136:232-40. 10.1017/S0950268807008564.

Kerlin MP, Weissman GE, Wonneberger KA, Kent S, Madden V, Liu VX, Halpern SD: Validation of administrative definitions of invasive mechanical ventilation across 30 intensive care units. Am J Respir Crit Care Med. 2016, 194:1548-52. 10.1164/rccm.201605-0953LE.

Introduction to the HCUP National Inpatient Sample (NIS). (2018). Accessed: April 19, 2022: https://www.hcup-us.ahrq.gov/db/nation/nis/NIS_Introduction_2018.jsp.

Berthelsen CL: Evaluation of coding data quality of the HCUP National inpatient sample. Top Health Inf Manage. 2000, 21:10-23.

Charu V, Simonsen L, Lustig R, Steiner C, Viboud C: Mortality burden of the 2009-10 influenza pandemic in the United States: improving the timeliness of influenza severity estimates using inpatient mortality data. Influenza Other Respir Viruses. 2013, 7:863-71. 10.1111/irv.12096.

Homan RJ: Seasonal Influenza in the United States 2016-2017. Society of Actuaries, Schaumburg, IL; 2017.

Su G, Jwagami M, Qiu X, et al.: Kidney disease and mortality in patients with respiratory tract infections: a systematic review and meta-analysis. Clin Kidney J. 2021, 14:602-11. 10.1093/ckj/sfz188.

Mailloux LU, Bellucci AG, Wilkes BM, Napolitano B, Mossey RT, Lesser M, Bluestone PA: Mortality in dialysis patients: analysis of the causes of death. Am J Kidney Dis. 1991, 18:526-35. 10.1016/S0272-6386(12)80091-6.

Bloomberger WE, Port FK, Mauger EA, Wolfe RA: A comparison of cause of death between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol. 1995, 6:184-91. 10.1681 ASN.962184.

Gilbertson DT, Rothman KJ, Chertow GM, et al.: Excess deaths attributable to influenza-like illness in the ESRD population. J Am Soc Nephrol. 2019, 30:546-53. 10.1681/ASN.2018060581.

Weng TC, Chiu HR, Chen SY, Shih FY, King CC, Fang CC: National retrospective cohort study to identify age-specific fatality risks of comorbidities among hospitalised patients with influenza-like illness in Taiwan. BMJ Open. 2019, 9:e025276. 10.1136/bmjopen-2018-025276.

Hespianhol V, Bárbara C: Pneumonia mortality, comorbidities matter?. Pulmonology. 2020, 26:123-9.

Estimates of influenza vaccination coverage among adults—United States, 2017–18 flu season. (2022). Accessed: April 24, 2022: https://www.cdc.gov/flu/fluvaxview/coverage-1718estimates.htm.

Remschmidt C, Wichmann O, Harder T: Influenza vaccination in patients with end-stage renal disease: systematic review and assessment of quality of evidence related to vaccine efficacy, effectiveness, and safety. BMC Med. 2014, 12:244. 10.1186/s12916-014-0244-9.

Danziger J, Weinhandl E, Friedman D, Mukamel BK: Racial and ethnic disparities in seasonal influenza vaccination among dialysis facilities in the United States. J Am Soc Nephrol. 2020, 31:2117-21. 10.1681/ASN.2020040485.